Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Juno Therapeutics Cancer Drug Trial Allowed to Continue

By Stephanie Guzowski | July 13, 2016

T cells attacking cancer cell

A CAR-T therapy trial by Juno Therapeutics that was halted last week following the death of three patients has been allowed to resume, the company announced.

Last week the U.S. Food and Drug Administration abruptly halted Juno’s clinical trial of an experimental treatment for leukemia after three patients died from swelling in the brain. The company said the deaths resulted not from the genetically engineered treatment but from fludarabine, a second chemotherapy drug used in its pre-treatment regimen. The FDA said the trial can continue if this chemotherapy drug is no longer used in the regimen.

Juno’s initial studies used only one chemotherapy drug, cyclophosphamide, to prime the immune system for the therapy.

CAR-T therapy involves extracting patients’ immune system T cells, genetically engineering them to target cancer cells, and infusing them back into the bloodstream.

Although the treatment is still unproven, CAR-T therapy has shown successful results in treating leukemia and lymphoma.

But CAR-T therapy can cause severe side effects, such as swelling in the brain and cytokine-release syndrome, a condition in which the infused T cells release a rapid amount of cytokines into the bloodstream, which can lead to dangerously high fevers and precipitous drops in blood pressure.

Read More: Juno, Kite Pharma Aim for 2017 CAR-T Therapy Approvals

Juno’s therapy, known as JCAR015, is in mid-stage testing, with 20 patients currently enrolled in the study.

Juno executives say they expect the therapy’s first approval to be in 2018. The company is competing against Kite Pharma and Novartis, all of which are racing to bring the first CAR-T therapy to market.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50